

## Who we are



Kyn Therapeutics is a clinical-stage biotechnology company specializing in the development of cancer therapeutics targeting well-characterized immuno-metabolic pathways. Based in Boston, Massachusetts, we launched in December 2017 with \$49M Series A funding provided by OrbiMed Advisors and Atlas Venture. Kyn is working toward bringing breakthrough therapies to patients suffering from cancer, particularly those who do not benefit from current treatments like checkpoint inhibitors.

## Our approach

Kyn is leveraging years of pre-clinical and clinical research to explore the full potential of immuno-metabolic targets to enhance anti-tumor immune responses. Led by a strong leadership team with deep expertise in translational and clinical development and an experienced Board of Directors, Kyn is building a pipeline of programs that have the potential, either as monotherapies or as a powerful adjunct to modern immunotherapies, to overcome broad immunosuppression by modulating both the innate and adaptive immune systems.

## Our pipeline

The Kyn Therapeutics pipeline targets three key nodes in validated metabolic pathways that drive immunosuppression.

PROGRAM	DISCOVERY	PRE-CLINICAL	PHASE 1	PHASE 2	Partners
<b>EP4 Receptor Antagonist</b> PGE2 Pathway	<b>MSS Colorectal Cancer<sup>1</sup></b>		>		
	<b>PD1/L1 Refractory NSCLC<sup>1</sup></b>		>		
<b>Aryl Hydrocarbon Receptor Antagonist</b> IDO/TDO and Other Pathways	>				
<b>Kynurenine Degrading Enzyme "Kynase"</b> IDO/TDO Pathway	>				

<sup>1</sup> Pembrolizumab provided through a supply agreement with Merck.  
<sup>2</sup> Celgene has exclusive options under a global strategic collaboration agreement.

We have initiated two clinical oncology studies of our first-in-class, oral and selective EP4 antagonist candidate in combination with Merck's pembrolizumab in checkpoint inhibitor-resistant populations. We are also performing IND-enabling studies for two development-candidates: 1) a potentially industry leading AHR antagonist program that addresses IDO/TDO, TLR, and other pathways, and 2) a unique Kynurenine-degrading therapeutic enzyme ("Kynase") program that completely inhibits the Kynurenine pathway in a manner that IDO selective inhibition is not able to achieve. The AHR and Kynase programs are the subject of an exclusive option by Celgene Corporation, under which Kyn is responsible for R&D activities through Phase 1b. Celgene can then assume a global license to the program, thereafter leading and funding global development and commercialization.

Kyn Therapeutics, 50 Northern Avenue, 7th Floor, Boston, MA 02210

info@kyntherapeutics.com



www.kyntherapeutics.com

## Snapshot

**Clinical-stage**

**3 programs**

**Celgene partnership**

**Boston, MA**

## Management

Mark Manfredi  
CEO

Douglas Carlson  
CFO

Jason Sager  
Interim CMO

Alfredo Castro  
SVP, Chemistry &  
Preclinical Development

Jeffrey Ecsedy  
SVP, R&D

Karen McGovern  
VP, Drug Discovery

Maude Tessier  
VP, Business Development

Michelle Zhang  
VP, R&D

James Nolan  
Head of CMC Operations

## Board of Directors

Ron Renaud  
Translate Bio

David Bonita  
OrbiMed

Jean-Francois Formela  
Atlas Venture

Iain D. Dukes  
OrbiMed

George Georgiou  
UT Austin

Atsushi Nagahisa  
AskAt, Inc.